In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers conclude that the controversial drug is only modestly effective and has no clear safety benefits.
Results 1 to 1 of 1
MEDiscuss • Medical News • New arrhythmia drug provides only modest efficacy and no clear safety benefits, say researchers
- April 6th, 2010 #1Bot
- Member since
- Jul 2007
- Posts
- 20,745
New arrhythmia drug provides only modest efficacy and no clear safety benefits, say researchers
QuoteRelated Posts
-
HPV vaccine works for boys: Study shows first clear benefits
By MedBot in forum Medical NewsReplies: 0Last Post: February 4th, 2011, 08:11 PM -
Inverse benefits due to drug marketing undermine patient safety and public health
By MedBot in forum Medical NewsReplies: 0Last Post: January 14th, 2011, 02:06 AM -
Antibiotic treatment for ear infections in kids provides only modest benefits, study finds
By MedBot in forum Medical NewsReplies: 0Last Post: November 17th, 2010, 01:52 AM -
Gene activity in the brain depends on genetic background: Implications for individual differences in drug safety and efficacy
By MedBot in forum Medical NewsReplies: 0Last Post: October 19th, 2010, 07:00 PM -
EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery
By MedBot in forum Medical NewsReplies: 0Last Post: March 14th, 2010, 03:00 PM
Posting Permissions
The information provided on this site is meant to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
All times are GMT. The time now is 05:16 PM.